BARTON JACQUELINE K 4

What Happened Jacqueline K. Barton, a director of Gilead Sciences, received equity awards on April 30, 2026: 1,146 restricted stock units (RSUs) and 4,884 derivative awards recorded as acquired at $0.00. Total awarded interest equals 6,030 shares; the RSUs and the derivative awards vested immediately per the filing. These were compensation grants (not open-market purchases or sales).

Key Details

• Transaction date: 2026-04-30; filing date: 2026-05-04 (Form 4 accession 0001183680-26-000002).
• Reported acquisition price: $0.00 for both items (grants).
• Total awarded: 1,146 RSUs + 4,884 derivative awards = 6,030 shares.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnotes: F1 = 1,146 RSUs granted under the 2022 Equity Incentive Plan; each RSU converts to one share and vested immediately. F2 = 100% of the shares subject to the stock option vested immediately upon grant.
• Filing timeliness: filing posted May 4 for the April 30 transaction; check the official Form 4 for any late-filing notation.

Context RSUs represent a contingent right to receive common stock (here vested immediately), and the derivative entry reflects option-like awards that also vested on grant—meaning Barton had immediate economic exposure but paid no cash (grant price $0). These are routine director compensation awards and do not, by themselves, indicate buying or selling sentiment in the open market.